K. Zatloukal The European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI) Kurt Zatloukal, Medical University of Graz, Austria.

Slides:

Advertisements

Similar presentations

QUALITY AND COSTS OF PRIMARY CARE IN EUROPE

Advertisements

European Strategy Forum on Research Infrastructures

1 First Task: Homepage for the Preparation of the Pilot Project News / Updates / Proceedings Policy background Implementation.

Research Infrastructures in Horizon 2020

November 2004 The Research Infrastructures in FP7 DG RTD – Directorate ‘Structuring ERA’

The ESFRI context. Clinical Trials as Instruments supporting Evidence-based Medical Practice. Dr Rafael de Andres Medina, Instituto de Salud Carlos III.

Research Infrastructures in Horizon 2020 CEA-Saclay Saclay, 10 October 2013 Ana ARANA ANTELO European Commission – DG Research & Innovation Head of Unit.

The New EU Framework Programme for Research and Innovation HORIZON 2020 Judit Fejes Executive Agency of Small and Medium Enterprises (EASME)

Health systems and long-term care for older people in Europe. Modelling the interfaces between prevention, rehabilitation, quality of services and informal.

European Strategy Forum on Research Infrastructures ESFRI ESFRI Roadmap of Research Infrastructures and the Israeli Perspective David Horn, Tel Aviv University.

National Institute on Aging Richard J. Hodes, M.D. Director,NIA/NIH/DHHS ADC Meeting – NIH Roadmap and Budget October 2003.

Building the Foundations for Better Health Health Services Organization.

1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical development Phase I Phase II Phase III Product.

Service System for Management and Sharing of Scientific Data in Medicine Depei Liu, Ph.D. Chinese Academy of Medical Sciences.

Working across sectors Building collaborative eco-systems Lars Sundstrom SARTRE.

05/09/2015www.ecrin.org1 European Clinical Research Infrastructures Network

© FIMM - Institute for Molecular Medicine Finlandwww.fimm.fi Nordic Bioethics Committee: Confidential Medical Information – ethics and legal perspectives.

Presidency of Council of Ministers National Committee for Biosafety, Biotechnology and Life Sciences (D.P.C.M. March 19, 2007)

1 Progress report: DISCONTOOLS Project Morgane Delavergne DISCONTOOLS Project Manager, September 22nd, 2009 Mirror Group Meeting Châtelain Hotel, Brussels.

1 Research Infrastructures in FP7 EUDET Annual Meeting 19 October 2006, Munich Dr. Gerburg Larsen European Commission, RTD-B.3 - Research Infrastructures.

Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.

1 Case Study Innovative Medicines Initiative (IMI) Karen Strandgaard EFPIA EuroConference, Brussels April 26th, 2006.

The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.

EPOS Preparatory phase Torild van Eck (ORFEUS) Call INFRA Deadline: December 3, 2009 Funding: between 3 and 6 MEuro Duration: max 4 year.

Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.

Telematikplattform für Medizinische Forschungsnetze (TMF) e.V. TMF – A Common Platform for Medical Research Networks in Germany Improving the Organisation.

FP7 Capacities Research Infrastructures (RI) in the field of Health Research Infrastructures (RI) in the field of Health Infrastructures NCPs: Radu TAMAIAN.

September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.

1 Support for New Research Infrastructures in the EU 7 th Framework Programme for Research Elena Righi European Commission SKADS Workshop, Paris, 4 September.

ESTELA Summer Workshop, 26 June 2013 The EU-SOLARIS project.

Report /03/ Athens Information Day on “Research Infrastructures in FP7” Robert Jan Smits European Commission 21 March 2007 Greece European.

Send correspondence to: Bartha Maria Knoppers Chair of Interim Board Centre de recherche en Droit Public Université de Montréal.

David Carr The Wellcome Trust Data management and sharing: the Wellcome Trust’s approach Economic & Social Data Service conference.

1 Direction scientifique Networks of Excellence objectives  Reinforce or strengthen scientific and technological excellence on a given research topic.

Vaccinomics: social and science systems in transition Farah Huzair Innogen, The Open University.

1 ASTRONET Coordinating strategic planning for European Astronomy.

EURORDIS Eurordis Position on Research Priorities for Rare Diseases.

Public Population Projects in Genomics International Working Groups Working Meeting September th, 2005, Hinxton, UK.

European Network for Biodiversity Information. Why ENBI ?

The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.

EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.

EUNetPaS is a project supported by a grant from the EAHC. The sole responsibility for the content of this presentation lies with the author(s). The EAHC.

EGEE-III INFSO-RI Enabling Grids for E-sciencE EGEE08 conference, Istambul Life sciences cluster perspective on EGI V. Breton, CNRS On.

CENTRE FOR SOCIAL INNOVATION Social innovation in Austria for Europe The Centre for Social Innovation (ZSI) researches and supports innovation processes.

Health Technology Assessment Methodology, an EUnetHTA View Basics for the Assessment in EU Countries PharmDr. Martin Visnansky, MBA, PhD., MSc. (HTA) HTA.

The Concept The format of BBMRI should be a distributed hub structure in which the hubs coordinate activities, including collection, exchange and analysis.

© UEG Presentation by Towards more coordination in health research: a report on the UEG research symposium 16/11/2012 Michael Manns General Assembly.

H. PERO, E uropean Commission European policy developments and challenges in the field of Research Infrastructures.

European Life Sciences Infrastructure for Biological Information ELIXIR’s needs from the EOSC Steven Newhouse, EMBL-EBI Part of the.

BioMedical Cluster New opportunities for innovators and investors with Bio-Medical Cluster of Skolkovo Foundation Innovation in Medical Technologies Conference,

European Life Sciences Infrastructure for Biological Information European Life Sciences Infrastructure for Biological Information.

Project Summary Human biological samples including associated medical data, and biomolecular research tools are key resources in unravelling the interplay.

The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.

Professor Orla Hardiman HRB Clinician Scientist Innovation Its role in Delivering Better Health Outcomes.

Professor John Womersley ESFRI Chair. ESFRI The European Strategy Forum on Research Infrastructures (ESFRI) was established in 2002 with a mandate from.

Anne Cambon-Thomsen, MD,

Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ

Margaret Mary Bertram, MPH Center for Global Health

partly FAIR, partly Cloudy

Davor Kozmus, MHEST Steering Platform Meeting 29. October 2009, Zagreb

WP2 Governance Per Öster

European Partnership Against Cancer, 08/12/2010

BioMedBridges – Work Packages 2 & 12

Clinical and Translational Science Awards Program

The International Consortium for Personalised Medicine

ESFRI ROADMAP Madrid, 12th March 2019 Gonzalo Arévalo Nieto

Experience of the implementation of FP6; preparations towards FP7

M-H Pinard-van der Laan

Update on Horizon Europe

Common Authentication and Authorisation Service for Life Science Research Mikael Linden, ELIXIR Finland.

Presentation transcript:

K. Zatloukal The European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI) Kurt Zatloukal, Medical University of Graz, Austria Needs and Challenges in Translational Medicine Rome, October 3 rd 2008

K. Zatloukal Biobanks in Cancer Research  NCI: Biological sampels are #1 roadblock  OECD: Global Biological Resource Centre Network  WHO/IARC: Standards for biological resource centres  ESF: Science Policy Briefing: Need for integration  EU/ESFRI: Research infrastructure for Biobanks and Biomolecular Resources (BBMRI) 700,000 Cancer deaths (North America; 2007) Cancer Genome Project struggels with sample shortage (Nature Medicine 2007) ELSI Fragmentation Funding Technical Follow-up

K. Zatloukal

Key Components of BBMRI Fam. history Lab. param. Treatm. outcome Lifestyle PBMC Serum FFPE tissues Frozen tissues Cells Antibodies Affinity binders Recomb. proteins Gene clone collections* siRNA libraries* Cell lines* Model organisms* Sample storage Human biological samples and data Healthy Population Patients Analysis tools Application Basic research Life sciences Targets for Drug discovery Biomarkers for Drug development New diagnostics Personalized medicine Public health Infrastructure Data storage Biocomputing DNA * : ESFRI BMS report but not funded

K. Zatloukal Research Infrastructures: The new dimension in life sciences research networks resources, technologies services Individual resarch groups pan-European research infrastructures Access Competition Innovation Cooperation Integration Harmonization

K. Zatloukal The Added Value of Cooperation Population-based biobanks Disease-oriented biobanks Technologies Biomolecular res. Model systems Genetics Laboratory medicine Pathology Many more….. Epidemiology Informatics Systems biology -omics technologies Microbiology Oncology

The Starting Point for a pan-European BBMRI 182 Associated organisations 27 Countries 50 Participating institutions Preparatory phase 27 months Funding 5 mio €

K. Zatloukal The Legal Structure of BBMRI (ERI) Distributed hub and spoke structure National members Biobanks Biomolecular res. Technology centers Associated partners Hospitals Universities Service providers … Headquarters

K. Zatloukal Organization (prep phase) Governance council (participants, ass. organizations) Executive Management Disease-oriented Biobanks WP3 Biomolecular resources Technologies WP4 Data bases Biocomputing WP5 Advisory board Stakeholder forum Funders Patients Clinicians Industry Partners Users Science Industry ELSI WP6 Population-based Biobanks WP2 Participants Funding Financing WP7 Participants Coordination board (external projects) Project Management WP1 Steering committee (WP leaders, chairs) Strategic Executive Operative Participants

K. Zatloukal Synergies of Research Infrastructures and Technology Platforms EATRIS ELIXIR INFRAFRONTIER ECRIN BBMRIINSTRUCT Target Id Target ValHitLead OptimPreclinincPhase IPhase II Research Discovery Development Phase III INNOVATIVE MEDICINES INITIATIVE EU- RI JTI e-Infrastructure Biobanking solutions

K. Zatloukal The Process Evaluation of existing resources and solutions Identification of open issues Concept for: Integration of existing resources Integration of future resources Process standardization, certification Access rules Incentives and benefit sharing International exchange of samples and data Operational concept Financial Plan Implementation Plan MoU, Contracts 8 mo 10 mo 3 mo

K. Zatloukal The Adaptor Approach of BBMRI  Define criteria Which samples and data can be combined? Need for evidence-based standards  Develop tools Data exchange Sample transport  Provide Access

K. Zatloukal Expected Impact of BBMRI  BBMRI provides framework to foster excellence in biomedical research Better projects, faster, cheaper  Certified biobanks & biological resource centres  Globally harmonized processes  Access to high quality resources, technologies, services  Partner for academia and industry SMEs: Strategic partner, customer Pharma: Biomarker and drug development

K. Zatloukal The Team: WP Leaders and Chairs Coordination/Executive Mgmnt.K. Zatloukal, AT; E. Vuorio, FI M. Yuille, UK; M Pasterk, FR Population-based Biobanks: L. Peltonen, FI/UK; A. Metspalu,EE Disease-oriented Biobanks: E. Wichmann, GER, T Meitinger, GER Biomolecular Resources:U. Landegren, SE; M. Taussig, UK Databases & Biocomputing:J-E Litton, SE Ethical, Legal and Societal Issues: A. Cambon-Thomsen, FR Funding and Financing: G. Dagher, FR; J. Ridder, NL C. Brechot, FR; Governance Council Chair: L. Peltonen, FI Advisory Board Chair: G-J van Ommen, NL Coordination Board Chair: K. Zatloukal, AT Stakeholder Forum Chair: M. Griffith, IR 50 Participants (6 Ministries, 18 Funding Organizations) 182 Associated Organizations 27 Countries

K. Zatloukal Further Information Kurt Zatloukal, M.D. Institute of Pathology Medical University of Graz Auenbruggerplatz 25 A-8036 Graz Austria Tel: M. Yuille et al. Briefing in Bioinformatics 9: (2008)